Nektar presents new data from REZOLVE-AD study of ACAAI

Nektar (NKTR) Therapeutics presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology, ACAAI, 2025 Annual Scientific Meeting. Rezpegaldesleukin is a first-in-class IL-2 pathway agonist and regulatory T-cell biologic currently being studied in a Phase 2b study in moderate-to-severe atopic dermatitis, REZOLVE-AD, and a separate Phase 2b study in patients with severe-to-very-severe alopecia areata, REZOLVE-AA. Key findings: Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma; Extended dosing with rezpegaldesleukin q2w supports 24-week induction period for planned Phase 3 studies with improvement across major efficacy endpoints from Week 16 to 24, including EASI-75, EASI-90, and vIGA-AD; Data from long-term maintenance portion of REZOLVE-AD with 52 weeks of treatment expected in Q1 2026 from REZOLVE-AD study.